Cullen Frost Bankers Inc. reduced its stake in Eli Lilly And Co (NYSE:LLY) by 6.0% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 26,076 shares of the company’s stock after selling 1,670 shares during the period. Cullen Frost Bankers Inc.’s holdings in Eli Lilly And Co were worth $2,916,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Bessemer Group Inc. boosted its holdings in shares of Eli Lilly And Co by 2,354.5% in the second quarter. Bessemer Group Inc. now owns 569,510 shares of the company’s stock valued at $63,096,000 after acquiring an additional 546,307 shares during the period. Cedar Capital LLC boosted its holdings in shares of Eli Lilly And Co by 17.5% in the second quarter. Cedar Capital LLC now owns 2,459 shares of the company’s stock valued at $272,000 after acquiring an additional 367 shares during the period. Assetmark Inc. boosted its holdings in shares of Eli Lilly And Co by 13.9% in the second quarter. Assetmark Inc. now owns 410,334 shares of the company’s stock valued at $45,461,000 after acquiring an additional 50,087 shares during the period. Haverford Trust Co. boosted its holdings in shares of Eli Lilly And Co by 60.3% in the second quarter. Haverford Trust Co. now owns 6,418 shares of the company’s stock valued at $711,000 after acquiring an additional 2,414 shares during the period. Finally, Naples Global Advisors LLC raised its stake in shares of Eli Lilly And Co by 1.1% during the second quarter. Naples Global Advisors LLC now owns 15,591 shares of the company’s stock worth $1,727,000 after purchasing an additional 170 shares during the last quarter. Hedge funds and other institutional investors own 77.22% of the company’s stock.

NYSE:LLY traded up $0.12 during trading hours on Friday, hitting $112.89. The company’s stock had a trading volume of 73,717 shares, compared to its average volume of 3,305,375. The business’s 50-day moving average is $110.64 and its two-hundred day moving average is $112.68. The company has a market capitalization of $106.81 billion, a PE ratio of 20.33, a PEG ratio of 1.82 and a beta of 0.16. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.88 and a current ratio of 1.17. Eli Lilly And Co has a 52-week low of $101.36 and a 52-week high of $132.13.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 23rd. The company reported $1.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.43 by $0.05. The firm had revenue of $5.48 billion during the quarter, compared to analysts’ expectations of $5.50 billion. Eli Lilly And Co had a return on equity of 107.99% and a net margin of 35.10%. Eli Lilly And Co’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.39 earnings per share. As a group, analysts predict that Eli Lilly And Co will post 5.78 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $0.645 dividend. This represents a $2.58 annualized dividend and a yield of 2.29%. The ex-dividend date is Thursday, November 14th. Eli Lilly And Co’s payout ratio is 46.49%.

Several equities research analysts have recently commented on the company. UBS Group cut their price target on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research note on Thursday, October 17th. Bank of America assumed coverage on Eli Lilly And Co in a research note on Wednesday, October 16th. They set a “buy” rating and a $133.00 price target for the company. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $130.03.

In other news, SVP Stephen F. Fry sold 9,452 shares of the firm’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $115.00, for a total value of $1,086,980.00. Following the completion of the transaction, the senior vice president now owns 100,211 shares in the company, valued at $11,524,265. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total value of $2,201,745.00. Following the completion of the transaction, the senior vice president now owns 38,306 shares of the company’s stock, valued at approximately $4,325,130.46. The disclosure for this sale can be found here. In the last quarter, insiders acquired 8,405 shares of company stock valued at $909,004 and sold 614,373 shares valued at $70,546,895. Corporate insiders own 0.11% of the company’s stock.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: What are Bollinger Bands?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.